IFNA1 and myeloid sarcoma: The Evidence of IFN Dose–response: European–North American Comparative Efficacy (EVIDENCE) study demonstrated that after 48 and 64 weeks of treatment, patients with MS were significantly less likely to relapse or have MRI activity if treated with s.c. IFN-β-1a 44 μg t.i.w., compared with i.m. IFN-β-1a 30 μg q.w. [28,29].